This application is directed to compounds of the formula ##STR00001##
wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W.sup.1 and
W.sup.2 are independently --O-- or --S(.dbd.O).sub.t--, where t is 0, 1,
or 2; Y is .dbd.C(R.sup.1.sub.a)--, where R.sup.1.sub.a is a member
selected from the group consisting of H; F; Cl; CN; NO.sub.2; --(C.sub.1
C.sub.4)alkyl; --(C.sub.2 C.sub.4)alkynyl; fluorinated-(C.sub.1
C.sub.3)alkyl; fluorinated-(C.sub.1 C.sub.3)alkoxy; --OR.sup.16; and
--C(.dbd.O)NR.sup.22.sub.aR.sup.22.sub.b; R.sup.22.sub.a and
R.sup.22.sub.b are defined as set forth in the specification; --R.sup.A
and R.sup.B are each a member independently selected from the group
consisting of H; F; CF.sub.3; --(C.sub.1 C.sub.4)alkyl; --(C.sub.3
C.sub.7)cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl,
and benzyl moieties are each independently substituted with 0 to 3
substituents R.sup.10, which is defined as set forth in the
specification; R.sup.16 and R.sup.17 are defined as set forth in the
specification; --R.sup.C and R.sup.D have the same meaning as defined
above for R.sup.A and R.sup.B except that one of them must be --H, and
they are selected independently of each other and of R.sup.A and R.sup.B;
R.sup.1 and R.sup.2 are each a member independently selected from the
group consisting of H; F; Cl; CN; NO.sub.2; --(C.sub.1 C.sub.4)alkyl;
--(C.sub.2 C.sub.4)alkynyl; fluorinated-(C.sub.1 C.sub.3)alkyl;
OR.sup.16; and --C(.dbd.O)NR.sup.22.sub.aR.sup.22.sub.b; --R.sup.3 is H;
--(C.sub.1 C.sub.3)alkyl; phenyl; benzyl; or OR.sup.16; R.sup.4, R.sup.5,
and R.sup.6 are defined as set forth in the specification; J.sup.1 and
J.sup.2 are each independently a moiety comprising a saturated or
unsaturated six-membered monocyclic carbon ring; and D is a member
independently selected from the group consisting of partial Formulas
(1.1.1) through (1.1.5) as set forth in the specification; a
pharmaceutically acceptable salt thereof; which are useful as inhibitors
of PDE4 in the treatment of diseases regulated by the activation and
degranulation of eosinophils, especially asthma, chronic bronchitis, and
chronic obstructuive pulmonary disease.
